A Comprehensive Board Review in Hematology and Medical Oncology

—A Virtual Live Streaming Course—

September 25-30, 2023

September 25-27, 2023: Benign and Malignant Hematology

September 26-30, 2023
Malignant Hematology and Solid Tumor









A Comprehensive Board Review in Hematology and Medical Oncology

— A Virtual Live Streaming Course —

GOAL

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.

EDUCATIONAL OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology
- Utilize current standards of care for patients with cancer, blood disorders and malignancies
- Demonstrate proficiency of knowledge in hematology and medical oncology
- Incorporate recent advances in management of hematologic and oncologic patients; and
- Define molecular determinants of cancer risk and apply this knowledge in practice.

TARGET AUDIENCE

This program should be of interest to Physicians, Advanced Practice Providers, APNs, and Nurses.

EDUCATIONAL METHODS

- Lectures/Didactic
- Case-based Question-and-Answer Sessions (in board examination format)
- · Virtual Live Streaming Course
- · Canvas an online course management system

EVALUATION

An online course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education

(ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 50.00 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC POINTS

American Board of Internal Medicine

CME MOC

Successful completion of this CE activity, which includes participation in the evaluation component,

enables the participant to earn up to 50.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CE credits claimed for the activity.

It is the CE activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. In order to receive MOC points, you must pass the post-test with a score of 70% or higher.

CE CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding *AMA PRA Category 1 Credit*™ or certificates documenting attendance will be available to participants once they complete the on-line evaluation. To obtain a CE certificate, physicians must complete the on-line evaluation questionnaire.

A record of attendance (certificate) will be available online to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

PLANNING COMMITTEE

MD Anderson Cancer Center

Sharon Giordano, MD, MPH, Co-Director Tapan Kadia, MD, Co-Director Shreyaskumar Patel, MD Alessandra Ferrajoli, MD Nishin Bhadkamkar, MD Felisha Estelle

Baylor College of Medicine Martha Mims, MD, PhD, Co-Director

AGENDA

Monday, September 25, 2023

All time is Central Daylight Time (CDT)

6:45 a.m. Virtual On-line Registration Check-in

7:15 a.m. Welcome and Introduction

Martha Mims, MD, PhD, Section Chief,

Hematology/Oncology, Baylor College of Medicine

BENIGN HEMATOLOGY SESSION

General Topics/Red Cell Disorders/Platelets

7:30 a.m. Iron Deficiency and Hemochromatosis

Matthew Heeney, MD

8:15 a.m. **Hematopoietic Growth Factors**

Martha Mims, MD, PhD

9 a.m. **Bone Marrow Failure**

Timothy Olson, MD, PhD

9:45 a.m. Break

10 a.m. Leukopenia and Leukocytosis

Nancy Berliner, MD

10:45 a.m. **Issues in Transfusion Medicine**

Kerry O'Brien, MD

11:45 a.m. Q & A Panel Discussion

Matthew Heeney, MD; Martha Mims, MD, PhD; Timothy Olson, MD, PhD; Nancy Berliner, MD;

and Kerry O'Brien, MD

12 p.m. Lunch Break

Coagulation/Platelets/Red Cell Disorders

12:30 p.m. Sickle Cell Anemias, Thalassemia,

and Hemoglobinopathies

Alice Ma, MD

1:15 p.m. **Hemolytic Anemias**

Gerald Soff, MD

2 p.m. **Approach to Anemia**

Alice Ma, MD

2:30 p.m. Break

2:45 p.m. **Disorders of Platelet Function**

A. Koneti Rao, MD, FACP

3:30 p.m. Charles A. Koller, MD Lectureship Award

2023 Recipient: Alvin Schmaier, MD

3:35 p.m. Thrombocytopenias

Alvin Schmaier, MD

4:15 p.m. Q & A Panel Discussion

Alice Ma, MD; Gerald Soff, MD; Alvin Schmaier, MD;

and A. Koneti Rao, MD, FACP

4:30 p.m. Adjourn

Tuesday, September 26, 2023

All time is Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

Platelet/Red Cell Disorders/Transfusion Medicine

7:30 a.m. Antithrombotic & Antiplatelet Therapy

Alvin Schmaier, MD

8:15 a.m. **Normal Coagulation**

Kenneth Bauer, MD

9 a.m. Break

9:15 a.m. Coagulation Factor Deficiencies, Including

von Willebrand's Disease and Hemophilias

Kenneth Bauer, MD

10 a.m. **Hypercoagulable States**

Stephan Moll, MD

11 a.m. Q & A Panel Discussion

Alvin Schmaier, MD; Kenneth Bauer, MD;

and Stephan Moll, MD

11:15 a.m. Benign Hematology Q & A Session

Senthil Sukumar, MD

11:55 a.m. Lunch Break

MALIGNANT HEMATOLOGY SESSION

Lymphoma/Myeloma

12:30 p.m. **Classification of Lymphoma**

Lynne Abruzzo, MD, PhD

1:15 p.m. **Aggressive Non-Hodgkin Lymphoma**

Christopher Flowers, MD

2 p.m. **Indolent Non-Hodgkin Lymphoma**

Loretta Nastoupil, MD

2:45 p.m. Break

3 p.m. Hodgkin Lymphoma

Alison Moskowitz, MD

3:45 p.m. Multiple Myeloma and Other Plasma Cell

Dyscrasias

S. Vincent Rajkumar, MD

4:45 p.m. **Q & A Panel Discussion**

Lynne Abruzzo, MD, PhD; Loretta Nastoupil, MD;

Christopher Flowers, MD; Alison Moskowitz, MD;

and S. Vincent Rajkumar, MD, PhD

5 p.m. Adjourn

Wednesday, September 27, 2023

All time is Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

Leukemia/MDS

7:30 a.m. **Chronic Myeloid Leukemia**

Jorge Cortes, MD

8:15 a.m. **Myelodysplastic Syndrome**

Tapan Kadia, MD

9:15 a.m. Acute Myeloid Leukemia

Courtney DiNardo, MD

10 a.m. Break

10:15 a.m. Acute Lymphoblastic Leukemia

Hagop Kantarjian, MD

11 a.m. Q & A Panel Discussion

Jorge Cortes, MD; Tapan Kadia, MD;

Courtney DiNardo, MD; and Hagop Kantarjian, MD

11:15 a.m. Malignant Hematology Q & A Session

Patrick Reville, MD

11:55 a.m. Lunch Break

MPN/CLL/SCT

12:30 p.m. Chronic Lymphocytic Leukemia

and Hairy Cell Leukemia

Susan O'Brien, MD

1:15 p.m. **Myeloproliferative Neoplasms**

Raajit Rampal, MD

2:15 p.m. Break

2:30 p.m. **Stem Cell Transplant Supportive Care**

Betty Hamilton, MD

3:30 p.m. Infectious Complications in Cancer Patients

Samuel Shelburne, MD, PhD

4:15 p.m. **Q & A Panel Discussion**

Susan O'Brien, MD; Raajit Rampal, MD;

Betty Hamilton, MD; and Samuel Shelburne, MD, PhD

4:30 p.m. Adjourn

Thursday, September 28, 2023

All time is Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

SOLID TUMOR SESSION

Pharmacology/Genetic Risk Factors/Sarcoma

7:30 a.m. **Pharmacology I: Chemotherapy**

Claire Mach, PharmD

8:30 a.m. **Pharmacology II: Targeted Therapy**

(Alk, EGFR, VEGR, HER2, HH, mTOR, PARP)

Whitney Lewis, PharmD

9 a.m. Break

9:15 a.m. **Pharmacology III: Targeted Therapy (CD20,**

CD30, CD33, Proteasome, BCR-ABL/KIT, FLT3,

IDH1/2, CDK4/6, PI3K) Brian Primeaux, PharmD

9:45 a.m. **Pharmacology IV: Immunotherapy**

Claire Mach, PharmD

10:05 a.m. Break

10:15 a.m. **Genetic Risk Factors**

Claudine Isaacs, MD

11 a.m. Sarcoma

Shreyaskumar Patel, MD

12 p.m. **Q & A Panel Discussion**

Claire Mach, PharmD; Whitney Lewis, PharmD;

Brian Primeaux, PharmD; Claudine Isaacs, MD; Shreyaskumar Patel, MD

12:15 p.m. Lunch Break

Breast Cancer

12:45 p.m. Screening/Local Management of Breast Cancer

Abenaa Brewster, MD

1:30 p.m. Systemic Treatment of Primary Breast Cancer

Including HER2 Positive Breast Disease

Lisa Carey, MD

2:30 p.m. **Break**

2:45 p.m. **Treatment of Metastatic Breast Cancer**

Including HER2 Positive Breast Disease Mariana

Chavez MacGregor, MD

3:45 p.m. **Special Issues in Breast Cancer**

Jennifer Litton, MD

4:15 p.m. **Q & A Panel Discussion**

Abenaa Brewster, MD; Lisa Carey, MD;

Mariana Chavez MacGregor, MD; and Jennifer Litton, MD

4:30 p.m. Solid Tumor Q & A - Session 1: Pharmacology/

Genetic Risk Factors/Sarcoma/Breast

Mark Lewis, MD

5:10 p.m. Adjourn

Friday, September 29, 2023

All time is Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

Lung Cancer/Head and Neck Cancer/Thyroid Cancer

7:30 a.m. Early Stage and Locally Advanced

Non-Small Cell Lung Cancer

Nasser Hanna, MD

8:15 a.m. Metastatic Non-Small Cell Lung Cancer

Nasser Hanna, MD

9:15 a.m. Small Cell Lung Cancer

Carl Gay, MD

9:45 a.m. Break

10 a.m. **Head and Neck Cancer**

William N. William, Jr., MD

10:45 a.m. **Thyroid Cancer**

Mimi Hu, MD

11:15 a.m. Q & A Panel Discussion

Nasser Hanna, MD; Carl Gay, MD;

William N. William, Jr., MD; and Mimi Hu, MD

11:30 a.m. ASH/ASCO Choosing Wisely Recommendations

Ravin Garg, MD

12:10 p.m. Lunch Break

Gastrointestinal Oncology

12:45 p.m. Pancreaticobiliary Cancers/Unknown Primary

Robert Wolff, MD

1:45 p.m. **Gastroesophageal Cancers**/

Hepatocellular Carcinoma

Harry Yoon, MD

2:45 p.m. Break

3 p.m. Colorectal Cancer: Biology

and Adjuvant Therapy Scott Kopetz, MD, PhD

3:30 p.m. Metastatic Colorectal Cancer and Anal Cancer

Scott Kopetz, MD, PhD

4:30 p.m. **Q & A Panel Discussion**

Robert Wolff, MD; Harry Yoon, MD;

and Scott Kopetz, MD, PhD

4:45 p.m. Solid Tumor Q & A - Session 2: Lung Cancer/

Head and Neck Cancer/Thyroid Cancer/ GI

Megan Dupuis, MD

5:25 p.m. Adjourn

Saturday, September 30, 2023

All time is Central Daylight Time (CDT)

7 a.m. Virtual On-line Registration Check-in

Genitourinary Oncology/Melanoma

7:30 a.m. **Testicular Cancer**

Timothy Gilligan, MD

8:30 a.m. Urothelial Cancer

Arlene Siefker-Radtke, MD

9:15 a.m. Renal Cell Carcinoma

Eric Jonasch, MD

10 a.m. Break

10:15 a.m. **Prostate Cancer**

Brad Carthon, MD

11:15 a.m. Melanoma

Rodabe Amaria, MD

12 p.m. Q & A Panel Discussion

Timothy Gilligan, MD; Arlene Siefker-Radtke, MD;

Eric Jonasch, MD; Brad Carthon, MD;

and Rodabe Amaria, MD

12:15 p.m. Lunch Break

Neuro-Onc/Gynecologic Oncology

1 p.m. **Neuro-Oncology**

Antonio Omuro, MD

1:45 p.m. **Cervical Cancer**

Alejandro Rauh Hain, MD

2:30 p.m. Break

2:45 p.m. **Uterine Cancer**

Shannon Westin, MD

3:15 p.m. **Ovarian Cancer and Unusual**

Ovarian Histologies

Shannon Westin, MD

4:15 p.m. **Q & A Panel Discussion**

Antonio Omuro, MD; Alejandro Rauh Hain, MD;

and Shannon Westin, MD

4:30 p.m. **Solid Tumor Q & A – Session 3: Genitourinary**/

Melanoma/Neuro-Oncology/Gyn Onc

Ravin Garg, MD

5:10 p.m. Adjourn

Guest Faculty

Lynne Abruzzo, MD, PhD

The Ohio State University Columbus, Ohio

Kenneth Bauer, MD

Beth Israel Deaconess Medical Center Boston, Massachusetts

Nancy Berliner, MD

Brigham and Women's Hospital Boston, Massachusetts

Bradley Carthon, MD, PhD

Emory Healthcare Atlanta, Georgia

Jorge Cortes, MD

Gerogia Cancer Center Augusta, Atlanta

Megan Dupuis, MD

Vanderbilt-Ingram Cancer Center at Wilson County Lebanon, Tennessee

Ravin Garg, MD

Johns Hopkins University Maryland Oncology Hematology -Annapolis Division Annapolis, Maryland

Timothy Gilligan, MD

Cleveland Clinic Cleveland, Ohio

Betty Hamilton, MD

Cleveland Clinic Cleaveland, Ohio

Nasser Hanna, MD

Indiana University School of Medicine Indianapolis, Indiana

Matthew Heeney, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center Boston, Massachusetts

Claudine Isaacs, MD

Georgetown University Washington, District of Columbia

Mark Lewis, MD

Intermountain Healthcare Murray, Utah

Alice Ma, MD

University of North Carolina – Chapel Hill School of Medicine Chapel Hill, North Carolina

Stephan Moll, MD

University of North Carolina School of Medicine Chapel Hill, North Carolina

Susan O'Brien, MD

University of California, Irvine Irvine, California

Timothy Olson, MD, PhD

Children's Hospital of Philadelphia Philadelphia, Pennsylvania

Antonio Omuro, MD

Yale Cancer Center New Haven, Connecticut

Barbara Pro, MD

Columbia University Herbert Irving Comprehensive Cancer Center New York, New York

S. Vincent Rajkumar, MD

Mayo Clinic – Minnesota Rochester, Minnesota

Raajit Rampal, MD, PhD

Memorial Sloan Kettering Cancer Center New York, New York

A. Koneti Rao, MD, FACP

Lewis Katz School of Medicine at Temple University Philadelphia, Pennsylvania

Alvin Schmaier, MD

Case Western Reserve University Cleveland, Ohio

Iberia Romina Sosa, MD, PhD

Fox Chase Cancer Center Philadelphia, Pennsylvania

William William, Jr., MD

BP Hospital Sao Paulo, Brazil

Harry Yoon, MD

Mayo Clinic – Minnesota Rochester, Minnesota

REGISTRATION INFORMATION

A Virtual Live Streaming Course

The Comprehensive Board Review in Hematology and Medical Oncology will be virtual. This program will be presented only as a live streaming course. You will receive an email from the course platform to log in and access the live course online approximately 3 days before the conference.

PRESENTATIONS:

The presentations will be pre-recorded. The speakers will be available for the live Q&A sessions. Course syllabus will not be printed. Presentations (slides) will be available online via the course platform and Canvas. The PowerPoint presentations will be posted online as PDFs prior to the conference. You will receive an invitation email with directives to log in Canvas after the conference adjourns.

- The Full Conference and Hematology Session will begin at 7:30 a.m. on Monday, September 25. The Hematology Session will adjourn at 4:30 p.m. on Wednesday, September 27. The full conference will adjourn at 5:10 p.m. on Saturday, September 30.
- The Oncology Session will begin at 12:30 p.m. on Tuesday, September 26 and adjourn at 5:10 p.m. on Saturday, September 30.

Advanced registration is encouraged. Please see the online registration fees page.

*NOTE: The conference registration fee includes the tuition, access to course virtual platform with PDFs of the slides and Canvas - online web-based system with recorded videos.

The deadline for advanced registration is Monday, September 11, 2023.

• Register online at https://mdanderson.cloud-cme.com/HMOBR2023

Telephone registrations are not accepted.

We accept the following forms of payment:

- Credit Cards (MasterCard, VISA, and American Express)
- Check (payable through U.S. banks only)
- Mail to: Continuing Professional Education Unit 1781
 The University of Texas MD Anderson Cancer Center P.O. Box 301407
 Houston, TX 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on the registration form.

REFUND/CANCELLATION POLICY

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **Monday**, **September 11, 2023.** No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. For additional information, contact Continuing Professional Education at 713-792-2223 or toll free at 866-849-5866.

Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.

In case of activity cancellation, the liability of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.

Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. Please check the website.

PAST CONFERENCES - REVIEWS AND TESTIMONIALS

"The conference was well worth my time. It is nice to be able to take in as much information as possible and have the option of talking to the speakers afterwards. If this board review is still around in ten years (I hope it is), I will certainly attend it again as I study for my recertification."

"Fantastic course! It helped pass my boards with flying colors!"

"As a first time attendee and visitor to MD Anderson, the overall organization and quality of activity was very impressive and met every expectation. Would recommend this activity to any colleague/associate."

"Excellent review course. The conference was well organized and ran smoothly."

"Exceeded expectations; worth every penny."

"Superb conference. Exceptional, impressive"

"Very well organized. Amazing how well support staff kept program on time, and fed everyone."

Please let us know what specific topics, issues, or questions you wish to see addressed or emphasized in this activity by emailing Continuing Professional Education at ContinuingEducation@mdanderson.org. All responses will be forwarded to the Course Directors for consideration.

SPECIAL ASSISTANCE

Contact Felisha Estelle in Continuing Professional Education at 713-745-0083 or 1-866-531-MOBR (6627) if you have any ADA accommodation needs.

CONFERENCE REGISTRATION - D125364

Comprehensive Board Review in Hematology and Medical Oncology

September 25-30, 2023

CONFERENCE REGISTRATION FEES

Full Conference - MDs, PhDs, D0s, PharmDs □ Postmarked on or before August 25, 2023. \$1,200 □ Postmarked on or before September 11, 2023 \$1,300 □ Postmarked after September 11, 2023 \$1,400
Full Conference - Residents/Fellows/MD Anderson Alumni* ☐ Postmarked on or before August 25, 2023. \$800 ☐ Postmarked on or before September 11, 2023 \$900 ☐ Postmarked after September 11, 2023 \$1,000
Hematology Session - 3 days (Monday - Wednesday) MDs, PhDs, DOs, PharmDs Postmarked on or before August 25, 2023. \$550 Postmarked on or before September 11, 2023 \$600 Postmarked After September 11, 2023 \$650
Hematology Session - 3 days (Monday - Wednesday) Residents/Fellows/MD Anderson Alumni* ☐ Postmarked On Or Before August 25, 2023
Oncology Session - 4 ½ days (Tuesday P.M Saturday) MDs, PhDs, DOs, PharmDs Postmarked on or before August 25, 2023. \$650 Postmarked on or before September 11, 2023 \$700 Postmarked after September 11, 2023 \$750
Oncology Session - 4 ½ days (Tuesday P.M Saturday) Residents/Fellows/MD Anderson Alumni* Postmarked on or before August 25, 2023. \$450 Postmarked on or before September 11, 2023 \$500 Postmarked after September 11, 2023 \$550
Advanced Practice Providers/Nurses/Advanced Practice Nurses*\$450 MD Anderson/Baylor Faculty/Staff\$500 MD Anderson/Baylor Clinical Fellows*

^{*}A letter of introduction from the program director or chairperson with registration form is required to claim this reduced fee.

Make check payble to:

The University of Texas MD Anderson Cancer Center

2023 HEMATOLOGY AND MEDICAL ONCOLOGY BOARD REVIEW: COMPREHENSIVE PROGRAM MATERIAL AVAILABLE FOR NON-ATTENDEES

Comprehensive source material can provide you with home-study material designed for fellows-in-training, physicians planning to take the Hematology or Medical Oncology certifying examination, or physicians wishing to review the established standards of care in Hematology or Medical Oncology.

The conference registration fee includes the tuition, access to the course virtual platform with PDFs of the slides and Canvas (online web-based system with recorded videos).

NOTE: The conference will be available through an online course management system (Canvas) where you will be able to view each recorded lecture. The full conference will be available approximately 12 days after the conference adjourns. Instructions for access to Canvas will be provided.

CE Credits and MOC Points are awarded only by attending the virtual live course.

Available option to obtain course material:

CANVAS - online web-based system with recorded videos (Log in instructions will be provided)

- Online site with downloadable audio & videos for the entire 2023 Course
- Each speaker's complete PowerPoint slide presentation (Adobe Acrobat PDF file)
- · Full color, just as presented
- Each speaker's list of references
- Please allow 3-5 business days to process order before receiving log in instructions

D125366/PS115369

NON ATTENDEES

Please note: Flash drives are no longer available to purchase.

Telephone orders are not accepted.

Register online at https://mdanderson.cloud-cme.com/HM0BR2023https://mdanderson.cloud-cme.com/HM0BR2023https://mdanderson.com/HM0BR2023https://mdanderson.com/HM0BR2023https://mdanderson.com/HM0BR2023https://mdanderson.com/HM0BR2023https://mdanderson.com/HM0BR2023https://mdander

Make check or money order payable to: The University of Texas MD Anderson Cancer Center. Please allow 3-5 business days to process order before receiving log in instructions.



The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented.

MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

;	Non-Profit Org.	U.S. Postage	PAID	Houston, TX	Permit No. 7052
Center					
The University of Texas MD Anderson Cancer Co	Continuing Professional Education - Unit 1781	176700/30/125364/41	1,0,00/30/123034/41	F.U. DUX 30140/	Houston, lexas 77230-1407